Berg D - Search Results

1

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W; PRIPS study group. Berg D, et al. Eur J Neurol. 2013 Jan;20(1):102-8. doi: 10.1111/j.1468-1331.2012.03798.x. Epub 2012 Aug 1. Eur J Neurol. 2013. PMID: 22852790

2

Relationship of substantia nigra echogenicity and motor function in elderly subjects.

Berg D, Siefker C, Ruprecht-Dörfler P, Becker G. Berg D, et al. Neurology. 2001 Jan 9;56(1):13-7. doi: 10.1212/wnl.56.1.13. Neurology. 2001. PMID: 11148229

3

Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings.

Berg D, Siefker C, Becker G. Berg D, et al. J Neurol. 2001 Aug;248(8):684-9. doi: 10.1007/s004150170114. J Neurol. 2001. PMID: 11569897 Clinical Trial.

4

Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.

Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G. Berg D, et al. Arch Neurol. 2002 Jun;59(6):999-1005. doi: 10.1001/archneur.59.6.999. Arch Neurol. 2002. PMID: 12056937

5

Therapeutic strategies for Parkinson's disease based on data derived from genetic research.

Riess O, Berg D, Krüger R, Schulz JB. Riess O, et al. Among authors: berg d. J Neurol. 2003 Feb;250 Suppl 1:I3-10. doi: 10.1007/s00415-003-1101-3. J Neurol. 2003. PMID: 12761628 Review.

6

Does ultrasound disclose a vulnerability factor for Parkinson's disease?

Behnke S, Berg D, Becker G. Behnke S, et al. Among authors: berg d. J Neurol. 2003 Feb;250 Suppl 1:I24-7. doi: 10.1007/s00415-003-1104-0. J Neurol. 2003. PMID: 12761631 Review.

7

Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra.

Felletschin B, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Sommer U, Zeiler B, Becker G, Riess O, Berg D. Felletschin B, et al. Among authors: berg d. Neurosci Lett. 2003 Nov 27;352(1):53-6. doi: 10.1016/j.neulet.2003.08.026. Neurosci Lett. 2003. PMID: 14615048

8

Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra.

Deplazes J, Schöbel K, Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Becker G, Riess O, Berg D. Deplazes J, et al. Among authors: berg d. J Neural Transm (Vienna). 2004 Apr;111(4):515-21. doi: 10.1007/s00702-004-0125-z. J Neural Transm (Vienna). 2004. PMID: 15057521

9

Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease.

Hering R, Petrovic S, Mietz EM, Holzmann C, Berg D, Bauer P, Woitalla D, Müller T, Berger K, Krüger R, Riess O. Hering R, et al. Among authors: berg d. Neurology. 2004 Apr 13;62(7):1231-2. doi: 10.1212/01.wnl.0000118285.18383.90. Neurology. 2004. PMID: 15079038 No abstract available.

10

Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.

Berg D, Merz B, Reiners K, Naumann M, Becker G. Berg D, et al. Mov Disord. 2005 Mar;20(3):383-5. doi: 10.1002/mds.20311. Mov Disord. 2005. PMID: 15486999

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,413 results

Search Page

Filters